Welcome to our dedicated page for CAMTEK SEC filings (Ticker: CAMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Camtek Ltd. filings document foreign-issuer current reports on operating results, customer orders, investor presentations, material agreements, capital structure and governance. The company’s Form 6-K disclosures include financial-result releases, order announcements for semiconductor inspection and metrology systems, and operating and financial review materials.
Camtek’s regulatory record also covers capital-structure activity, including convertible senior notes due 2030, and risk disclosures tied to semiconductor capital spending, demand for HPC, HBM and chiplet devices, global trade and export restrictions, and geographic concentration in Asia Pacific markets. These filings describe the company as a Nasdaq- and TASE-listed supplier serving IDMs, OSATs and foundries.
Camtek Ltd (CAMT) director Aviram Lior reported selling a total of 6,694 ordinary shares in four open-market transactions on August 11–12, 2026, at prices between 162.0000 and 175.0000 per share. The Rule 10b5-1 checkbox was not selected. A footnote explains that one additional share had been omitted from a prior Form 3 due to a rounding error.
Camtek Ltd. Chief Financial Officer Moshe Eisenberg reported open-market sales of Camtek ordinary shares. On 2026-08-12 he sold 645 shares at $172.6717 per share. On 2026-08-11 he sold 3,759 shares at a weighted average price of $160.0561, in multiple trades between $160.00 and $160.5651 per share.
Camtek Ltd is the issuer on an amended Rule 144 notice covering ordinary shares to be sold through Oppenheimer & Co. Inc. The notice lists shares that were issued upon vesting of RSUs on several dates, including tranches of 9,738, 5,564, 2,206, 7,420 and 1,307 shares, all received for no cash consideration. The ordinary shares are shown as trading on Nasdaq with a reference date of 08/11/2026.
Camtek Ltd filed a notice of proposed sale of 415 ordinary shares under Rule 144. The shares were originally issued upon vesting of RSUs on 04/01/2025 for no cash consideration. Oppenheimer & Co. Inc. is listed as the broker, with an aggregate market value of $68,230.15 for the planned sale and 45,828,133 ordinary shares outstanding. The approximate sale date is 08/12/2026 on Nasdaq.
Lior Aviram filed a Form 144 in connection with ordinary shares of Camtek Ltd.. The notice covers a proposed sale of 3,347 ordinary shares of Camtek through Oppenheimer & Co. Inc., listed on Nasdaq, with an aggregate market value of $583,047.40. The shares were issued on 06/01/2026 upon vesting of RSUs for no cash consideration. The filing also notes that 3,347 ordinary shares were sold on 08/11/2026 for $545,530.00.
Camtek Ltd filed a notice for the potential sale of 3,296 Ordinary Shares through Oppenheimer & Co. Inc. on Nasdaq around 08/11/2026, with an aggregate market value of 521097.60 and 45828133 shares outstanding. The shares were acquired via RSU vestings of 9,738 shares on 01/16/2024, 5,564 on 02/15/2024, and 2,206 on 04/01/2025, each for no cash consideration.
A holder of Camtek Ltd. ordinary shares plans a potential sale of up to 3,347 shares through Oppenheimer & Co. Inc. on Nasdaq, with a proposed sale date of August 11, 2026. These shares were issued on June 1, 2026 upon vesting of RSUs for no cash consideration.
Phoenix Financial Ltd. reports beneficial ownership of 2,386,572.96 Camtek Ltd. ordinary shares, representing 5.12% of the class, based on 46,656,521 ordinary shares outstanding as of August 9, 2026. All voting and dispositive powers over these shares are shared, with no sole power reported.
As of August 6, 2026, the position was held across several Phoenix group entities, including trust funds, "nostro" accounts, pension and provident funds, linked insurance policies, and two partnerships whose ownership rights belong to Phoenix group companies. Phoenix and its subsidiaries state that each subsidiary operates under independent management and disclaims group status and beneficial ownership beyond actual pecuniary interest.
Camtek Ltd. reported record second-quarter 2026 revenue of $133.2 million, an 8% increase from $123.3 million a year earlier. GAAP gross profit was $66.7 million with a 50.1% gross margin, slightly below 50.8% in the prior-year quarter. GAAP operating income was $27.2 million (20.4% margin), down 15% from $32.0 million, mainly reflecting higher R&D and selling, general and administrative expenses. GAAP net income declined 31% to $23.3 million, or $0.46 per diluted share.
On a non-GAAP basis, gross profit was $68.5 million (51.4% margin) and operating income was $36.0 million (27.0% margin). Non-GAAP net income rose 2% to $39.4 million, or $0.78 per diluted share. Management cited acquisition-related expenses and a $7.7 million one-time tax expense among non-GAAP adjustments. Year-to-date orders exceeded $600 million, contributing to record backlog, and management expects Advanced Packaging revenue to grow about 70% between the first and fourth quarters of 2026.
Camtek guided third-quarter 2026 revenue to $158–$160 million, representing about a 20% sequential increase. It also expects more than 30% growth in second-half 2026 revenue versus first-half 2026, with continued growth into 2027. The balance sheet remains strong, with $815.8 million in cash, deposits and marketable securities as of June 30, 2026, against $488.5 million of convertible notes and total shareholders’ equity of $710.2 million.
Camtek Ltd director Shacham Yosef reported equity awards on July 29, 2026. He received 254 restricted stock units, each representing a contingent right to one ordinary share, and 571 stock options with a 147.87 per-share exercise price expiring July 29, 2033. Both awards vest at Camtek's 2027 annual shareholders meeting, and he now directly holds 6,734 ordinary shares plus 571 options.